Literature DB >> 20795647

Matrix metalloproteinase 9 targeting peptides: syntheses, 68Ga-labeling, and preliminary evaluation in a rat melanoma xenograft model.

Tiina Ujula1, Merja Huttunen, Pauliina Luoto, Hannu Peräkylä, Ilkka Simpura, Ian Wilson, Mathias Bergman, Anne Roivainen.   

Abstract

Biopanning of tumor cells was used in order to identify matrix metalloproteinase 9 (MMP-9) targeting peptides. The tumor cell targeting peptide (TCTP-1) and two modified versions thereof were evaluated as imaging agents for positron emission tomography (PET) using a rat melanoma xenograft model. For the PET imaging purposes, the 3 peptides were 1,4,7,10-tetraazacyclo-dodecane-N',N'',N''',N''''-tetraacetic acid (DOTA) conjugated and labeled with Gallium-68 ((68)Ga) and preliminarily evaluated: (1) cyclic (68)Ga-DOTA-TCTP-1 with cystine bridge, (2) cyclic (68)Ga-DOTA-lactam-TCTP-1 with a lactam bridge, and (3) linear (68)Ga-DOTA-lin-TCTP-1. The whole-body distribution kinetics and tumor targeting of the intravenously administered (68)Ga-DOTA-peptides were evaluated in vivo by PET and ex vivo by measuring the radioactivity of excised tissues. In addition, the in vivo stability of the radiolabeled peptides in rat plasma, tumor tissue, and urine was studied. All (68)Ga-DOTA-peptides were cleared via the liver and kidneys, and approximately 44% of injected radioactivity was excreted in urine during 120 min after injection. Ex vivo biodistribution studies showed a tumor-to-muscle ratio of 5.5 ± 1.3 (mean ± SD) for (68)Ga-DOTA-TCTP-1, 3.2 ± 0.2 for (68)Ga-DOTA-lactam-TCTP-1, and 3.2 ± 0.6 for (68)Ga-DOTA-lin-TCTP-1 at 120 min after injection. The (68)Ga-DOTA-lactam-TCTP-1 peptide appeared to be the most stable in vivo. The fraction of intact (68)Ga-DOTA-lactam-TCTP-1 in tumor was 59 ± 4.2% at 120 min after injection. The stability was moderate for (68)Ga-DOTA-TCTP-1 and poor for (68)Ga-DOTA-lin-TCTP-1. The possibility of imaging tumors that overexpress MMP-9, such as melanoma, by using radiolabeled TCTP peptides in PET imaging makes these peptides highly attractive for diagnostic and therapeutic applications. However, further modifications to improve the stability and affinity of the peptides are needed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20795647     DOI: 10.1021/bc1000643

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  11 in total

1.  Playing slot to hitting the jackpot in molecular imaging: On probability of uncovering subcellular pathogenesis vs achieving clinical applicability.

Authors:  Hans J de Haas; Jagat Narula
Journal:  J Nucl Cardiol       Date:  2017-03-28       Impact factor: 5.952

2.  Evaluation of 68Ga-labeled peptide tracer for detection of gelatinase expression after myocardial infarction in rat.

Authors:  Max Kiugel; Ville Kytö; Tiina Saanijoki; Heidi Liljenbäck; Olli Metsälä; Mia Ståhle; Johanna Tuomela; Xiang-Guo Li; Pekka Saukko; Juhani Knuuti; Anne Roivainen; Antti Saraste
Journal:  J Nucl Cardiol       Date:  2016-12-02       Impact factor: 5.952

3.  One-step and one-pot-two-step radiosynthesis of cyclo-RGD-(18)F-aryltrifluoroborate conjugates for functional imaging.

Authors:  Ying Li; Jinxia Guo; Shiqing Tang; Lixin Lang; Xiaoyuan Chen; David M Perrin
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-01-05

Review 4.  Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.

Authors:  Orit Jacobson; Xiaoyuan Chen
Journal:  Pharmacol Rev       Date:  2013-09-24       Impact factor: 25.468

5.  Towards Optimized Bioavailability of 99mTc-Labeled Barbiturates for Non-invasive Imaging of Matrix Metalloproteinase Activity.

Authors:  Lisa Honold; Melanie Austrup; Andreas Faust; Christian Paul Konken; Katrin Schwegmann; Bastian Zinnhardt; Constantin Gabriel Daniliuc; Günter Haufe; Michael Schäfers; Klaus Kopka; Sven Hermann
Journal:  Mol Imaging Biol       Date:  2021-11-08       Impact factor: 3.484

Review 6.  Prospective of ⁶⁸Ga-radiopharmaceutical development.

Authors:  Irina Velikyan
Journal:  Theranostics       Date:  2013-12-10       Impact factor: 11.556

Review 7.  Prospective of 68Ga Radionuclide Contribution to the Development of Imaging Agents for Infection and Inflammation.

Authors:  Irina Velikyan
Journal:  Contrast Media Mol Imaging       Date:  2018-01-04       Impact factor: 3.161

Review 8.  A Promising Biocompatible Platform: Lipid-Based and Bio-Inspired Smart Drug Delivery Systems for Cancer Therapy.

Authors:  Min Woo Kim; Seung-Hae Kwon; Jung Hoon Choi; Aeju Lee
Journal:  Int J Mol Sci       Date:  2018-12-04       Impact factor: 5.923

9.  Evaluation of [68Ga]Ga-DOTA-TCTP-1 for the Detection of Metalloproteinase 2/9 Expression in Mouse Atherosclerotic Plaques.

Authors:  Max Kiugel; Sanna Hellberg; Meeri Käkelä; Heidi Liljenbäck; Tiina Saanijoki; Xiang-Guo Li; Johanna Tuomela; Juhani Knuuti; Antti Saraste; Anne Roivainen
Journal:  Molecules       Date:  2018-12-01       Impact factor: 4.411

10.  Peptide-based selective inhibitors of matrix metalloproteinase-mediated activities.

Authors:  Margaret W Ndinguri; Manishabrata Bhowmick; Dorota Tokmina-Roszyk; Trista K Robichaud; Gregg B Fields
Journal:  Molecules       Date:  2012-11-30       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.